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Phase II Clinical Trial of GM-CSF Treatment in Patients 
with Hormone-Refractory or Hormone-Naïve Adenocarcinoma 
of the Prostate
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Abstract: The objective of this Phase II clinical trial was to determine the effects of chronic GM-CSF dosing on PSA levels 
in men with hormone-refractory or hormone-naïve prostate cancer. Six hormone-refractory and 10 hormone-naïve patients 
were recruited from an institutional practice and were treated with 250 and 125 μg/m
2 of GM-CSF, respectively, 3 times 
per week for continuous 12-week treatment cycles until evidence of disease progression, as indicated by 2 consecutive rising 
PSA levels. PSA levels were measured every 6 weeks. Of the 6 hormone-refractory patients, 2 were classiﬁ  ed with progres-
sive disease after 4 months and 1 after 1.75 months. The best PSA responses for the remaining 3 patients were 3%, 12%, 
and 32% declines which lasted from 1.75 to 8.5 months. Of the 10 hormone-naïve patients, 2 were classiﬁ  ed with progres-
sive disease after 3 and 12 months, and 1 patient met the criteria for stable disease after 7.75 months. The best PSA response 
for the remaining 7 patients ranged from 7% to 42% declines which lasted from 0.5 to 10 months. These results indicate 
that further study of GM-CSF administration is not warranted for hormone-refractory patients but is recommended for 
hormone-naïve patients using a chronic dosing regimen.
Keywords: prostate-speciﬁ  c antigen, prostate cancer, androgen independent, hormone therapy, immunotherapy, GM-CSF
Introduction
Currently, no standard treatment exists for advanced prostate cancer patients with biochemical relapse 
(BCR) as deﬁ  ned by rising PSA levels after deﬁ  nitive local therapy. Three-year follow-up data extracted 
from the caPSURE database revealed that BCR occurred in 27% of patients after radiation therapy, 22% 
of patients after cryotherapy, and 14% of the patients after radical prostatectomy.
1 Furthermore, BCR 
occurred in approximately one third of prostate cancer patients within 10 years of radical prostatectomy.
2,3 
While hormone therapy has provided clinical beneﬁ  t for 24–36 months when initiated at the time of 
clinical evidence of metastatis,
2 it remains palliative with extension of 5-year survival rates by merely 
2%–3% in select high-risk patients
4 and remains the last treatment option after local therapy failure.
2,5 
In addition, patients may be reluctant to begin hormone therapy treatment due to many adverse side 
effects, including decreased muscle mass, loss of libido, hot ﬂ  ashes, mild anemia, and increased risk of 
osteoporosis,
6 and some patients who receive early hormone therapy develop androgen-independent 
rising PSA levels while still asymptomatic and without radiographic evidence of disease progression.
2 
Other therapeutic treatments for rising PSA include observation alone or radiation treatment to the 
prostate or prostate bed. Since few effective treatments are available for patients with PSA-only progres-
sion and because persistent post-treatment PSA levels are indicative of poor prognosis, these patients 
make ideal candidates for clinical trials of novel drug treatments designed to reduce PSA levels.
Several clinical trials have shown that immune modulation by cytokines may be a promising therapy 
for malignancies.
7 The cytokine GM-CSF regulates granulocyte and macrophage differentiation and 
function and has been shown to induce dendritic cell antitumor activity.
8 Several recent clinical trials 
have reported that treating hormone-refractory patients with GM-CSF alone or in combination with 
thalidomide is mildly effective at decreasing PSA levels.
The current study reports the results of a Phase II clinical trial which examined the effects of GM-CSF 
on PSA levels in patients with BCR after failure of primary treatment with radiotherapy, radical pros-
tatectomy, or both. The PSA responses to GM-CSF treatment of both hormone-refractory patients 472
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(progressive disease despite hormone therapy) and 
hormone-naïve patients (no prior hormone therapy) 
were measured to determine whether use of the 
GM-CSF regimen warrants further study in both 
groups.
Patients and Methods
This study was approved by the Institutional 
Review Board Committee at Baylor College of 
Medicine. Patient eligibility criteria included his-
tological conﬁ  rmation of adenocarcinoma of the 
prostate, disease progression evidenced by 2 con-
secutive rises in PSA levels over 4 weeks (with or 
without radiographic involvement), life expectancy 
of at least 3 months, and Zubrod performance 
status  2. For the hormone refractory patients, 
additional eligibility criteria included failure of 
conventional hormonal treatment, antiantigen 
withdrawal, and serum testosterone levels 
of  50 ng/dl. Medically castrated patients 
continued testicular suppression therapy during 
enrollment. For hormone naïve patients, testoster-
one levels of  200 ng/dl were required. The 
patients did not receive concurrent chemotherapy 
or immunotherapy. No hormone refractory patient 
received more than 1 cytotoxic therapy from which 
they were fully recovered (at least 6 weeks) prior 
to enrollment. Each patient had an absolute 
peripheral granulocyte count  1500, a platelet 
count  100 000, bilirubin  1.5 mg/dl, serum 
glutamic pyruvic transaminase  2 times the upper 
limits of normal, and a serum creatinine  1.5 mg/dl. 
All patients gave written informed consent prior 
to initiation of study treatment.
Prior to treatment, a complete medical history, 
physical examination, chest x-ray, bone scan, and 
CT scan of the abdomen and pelvis were per-
formed. In addition, each patient underwent a 
complete blood count with differential, platelet 
count, urinalysis, albumin, alkaline phosphatase, 
AST calcium, LDH, total bilirubin, BUN, creati-
nine, inorganic phosphorus, electrolytes, PSA, 
CEA, testosterone, PT, and PTT measurements. 
For each 12-week treatment cycle, hormone-
refractory patients were subcutaneously injected 
with 250 μg/m
2 GM-CSF and hormone-naïve 
patients were injected with 125 μg/m
2 3 times per 
week with at least 24 hours between injections. 
Serum PSA levels were measured every 6 weeks. 
When an elevated PSA was found, a conﬁ  rmatory 
measurement was taken 2 weeks later. At the end 
of each 12-week treatment cycle, serum chemistry 
proﬁ  les, bone scans, plain ﬁ  lms, CT scans, and 
physical exams were performed. At least 3 treat-
ment cycles were completed unless intolerable 
toxicity (grade 3 or 4) developed, as evalu-
ated using the NCI Common Toxicity Criteria, 
Version 2.0.
9 Twelve-week treatment cycles were 
continued until disease progression.
Responses to treatment were classified as 
(1) complete response if PSA normalized and 
radiographic evidence of disease resolution was 
maintained for at least 8 weeks; (2) partial response 
if a  50% decrease in the sum of the prod-
ucts of all measurable lesions and a  50% 
PSA decline without normalization was maintained 
for 12 weeks; (3) stable disease if the criteria for 
complete response, partial response, or progressive 
disease were not met (i.e. no disease progression 
or improvement); and (4) progressive disease if 
3 consecutive increases in PSA to  25% above 
the nadir were measured at least 2 weeks apart, if 
the sum of the products of any measurable lesions 
or the estimated size of nonmeasurable lesions 
increased by  25%, or if new lesions appeared.
Statistical Methods
The primary objectives were to assess PSA 
response to treatment with GM-CSF in a group of 
hormone refractory patients and a separate group 
of hormone naïve patients. A decline in PSA level 
of  50% from baseline was considered to be of 
special clinical interest. Secondary objectives 
included assessment of overall survival and treat-
ment duration. Overall survival was calculated 
from the date of enrollment to the date of death. 
Treatment duration was calculated as the time 
between the ﬁ  rst treatment and the time the patient 
was taken off the study (i.e. stopped treatment). 
Duration of PSA response was deﬁ  ned as the time 
from the ﬁ  rst PSA decline of   50% to PSA    25% 
above the nadir.
The study design called for recruiting a 
maximum of 22 patients in both groups. Eight 
responses among hormone-refractory patients or 
15 responses in the hormone-naïve patients would 
warrant further study of GM-CSF in these popula-
tions, respectively. However, this trial was closed 
before the targeted number of patients was enrolled 
because none of the hormone-refractory patient 
achieved sufﬁ  cient PSA declines to warrant con-
tinuing the study. Based on the encouraging 473
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responses we observed in hormone-naïve patients, 
along with promising results achieved in studies of 
combination therapy of GM-CSF and thalidomide 
in this population,
2 hormone-naïve patients were 
moved into a trial of GM-CSF plus thalidomide.
Results
Ten patients with hormone-naïve adenocarcinoma 
of the prostate were enrolled and treated. Their 
median baseline PSA was 6.20 ng/ml and ranged 
from 2.6 to 14.2 ng/ml (Table 1). One patient had 
both bone and nodal metastases. Members of this 
group participated in the study for a median of 
7.9 months (Table 3). Median overall survival was 
47.6 months and ranged from 41.5 to 52 months. 
Two patients developed progressive disease after 
1 and 4 treatment cycles, respectively. One patient 
met the criteria for stable disease designation after 
7.75 months. For the 7 remaining patients, the best 
PSA response ranged from 7% to 42% decline.
Six patients were enrolled and treated in the 
hormone refractory arm. Median baseline PSA 
was 32 ng/ml and ranged from 2.6–42.6 ng/ml 
(Table 2). One patient had bone metastasis. The 
median duration of enrollment was 5.8 months 
(1.75 to 18.25 months) for hormone-refractory 
patients (Table 3). Median overall survival was 
38.1 months and ranged from 19.75 to 51.5 months. 
Two patients met the criteria for progressive 
disease designation after 4 months of enrollment 
and one at 1.75 months. For the remaining 
3 patients, the best PSA response ranged from 
3% to 32% decline.
Nonhematologic toxicity as a result of GM-CSF 
administration was minimal (Table 4); grade 1 
edema, fever, chills, bruising, herpes zoster, and pain 
were each reported by one patient. One patient had 
grade 3 thrombosis. Common hematologic toxicities 
included grade 1 hyperglycemia, grade 2 leukopenia, 
and grade 2 elevated leukocytes. One patient each 
had grade 3 leukopenia, grade 3 neutropenia, and 
grade 4 neutropenia (Table 4).
Discussion
Rising PSA levels after primary treatment for 
prostate cancer are problematic as deﬁ  nitive treat-
ment regimens have not yet been established. There 
is no compelling evidence that hormone treatment 
improves survival for patients with rising PSA 
levels
4, and the PSA level at which hormone treat-
ment should begin is not known. Adverse effects 
signiﬁ  cantly affect quality of life and may make 
patients reluctant to begin or continue hormone 
therapy. Furthermore, a subgroup of patients has 
been shown to develop androgen-independent 
prostate cancer after hormone treatment. Thus, 
treatment decisions must balance the need for 
disease management with the patient’s quality of 
life and overall survival.
Recently, use of GM-CSF has been examined 
as a means to halt rising PSA levels. In a Phase II 
clinical trial study, Dreicer et al. reported only 
1 hormone-refractory patient out of 9 with a PSA 
response that was  50% and 5 patients with PSA 
responses that were  50% when treated with 
250 μg/m
2 GM-CSF 3 times per week for 6 months. 
Table 1. Patient characteristics within the hormone-naïve arm.
Median (range) % (n)
Age, years 64.0 (53–83)
Primary therapy
Radical prostatectomy 60 (6)
   Radical prostatectomy + radiotherapy 10 (1)
   Radiotherapy + gene therapy 10 (1)
 Radiotherapy 20 (2)
Baseline PSA 6.20 (2.6–14.2) ng/ml
Metastatic Disease
 PSA  only 90 (9)
 Bone 0 (0)
  Bone and Nodal   10 (1)474
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In addition, 3 patients were classiﬁ  ed with progres-
sive disease after 4 months of treatment.
10 When 
treated daily with 250 μg/m
2 GM-CSF for 14 days 
followed by 250 μg/m
2 GM-CSF 3 times per week 
until disease progression, only 1 of 13 hormone-
refractory patients had a 6-week sustained PSA 
decline of  50%, while 12 patients experienced a 
PSA decline with a median of 32% (no range was 
reported).
11 Interestingly, 5 of 22 hormone-
refractory patients had  50% PSA decline when 
the 250 μg/m
2 GM-CSF 3 times per week regimen 
was combined with a maximum daily dose of 
200 μg of thalidomide,
2 suggesting that the 
combination of an immunostimulatory agent with 
anti-inﬂ  ammatory agent may be of more beneﬁ  t to 
hormone-refractory patients.
In the current study, 3 of the 6 patients recruited 
for the hormone-refractory arm had progressive 
disease designations within 4 months of systemi-
cally administered GM-CSF treatment. The best 
PSA response of the remaining 3 patients was a 
32% decline that lasted for 8.5 months of treatment. 
Results among the few hormone-refractory patients 
treated in this study do not appear as promising as 
the earlier reports. For this reason, we closed this 
trial early and do not recommend further study 
of the effects of GM-CSF on PSA levels in 
hormone-refractory patients at this time.
Schwaab et al. examined the immune response 
to GM-CSF administration and found little GM-CSF 
effect on PSA-speciﬁ  c CD+ and CD8+ T cell precur-
sors. Seven of 14 patients experienced  25% drops 
in PSA levels and 1 had a  50% decline, but prior 
hormone treatment status of these patients was not 
reported. They concluded that administration of 
GM-CSF alone produced little therapeutic beneﬁ  t 
and was unable to induce a PSA-speciﬁ  c T cell 
immunity; however, the existent PSA immunity in 
these patients suggests that they may beneﬁ  t from 
immune-stimulatory therapies.
12
In the current study, treatment of hormone-naïve 
patients with 125 μg/m
2 GM-CSF 3 times per week 
produced a better response. While 2 patients had 
progressive disease designations and 1 was classiﬁ  ed 
with stable disease, 7 patients had  50% PSA 
decline that lasted from 0.5–10 months. Dreicer et al. 
had similar results when hormone-naïve patients 
were treated with 250 μg/m
2 GM-CSF 3 times per 
week for up to 6 months. One patient had disease 
progression while 5 had  50% PSA decline.
10
These data from our study and others suggest 
that GM-CSF has some biological activity in 
Table 2. Patient characteristics within the hormone-refractory arm.
Median (range) % (n)
Age, years 76 (59–87)
Primary therapy
 Radical  prostatectomy 33 (2)
 Radical  prostatectomy  + radiotherapy 33 (2)
 Radiotherapy 33 (2)
Baseline PSA 32 (2.6–42.6) ng/ml
Metastatic Disease
 PSA  only 83 (5)
 Bone 16 (1)
  Bone and Nodal 0 (0)
Table 3. Patient response characteristics.
Arm Time on study 
median (range) 
months
Best PSA response 
median% (range)
PSA duration 
median (range) 
months
Overall survival 
median (range) 
months
Hormone naïve 7.9 (3–14) 10 (7–42)* 2.66 (0–10) 47.55 (41.5–52)
Hormone refractory 5.8 (1.75–18.25) 12 (3–32)
† 1.9 (0–8.5) 38.1 (19.75–51.5)
*n = 7, 2 patients had progressive disease and 1 patient was classiﬁ  ed as stable.
†n = 3, 3 patients had progressive disease.475
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patients with rising PSA levels. The promising 
results of GM-CSF/thalidomide combination treat-
ment of hormone-refractory patients
2 combined 
with the response of PSA-only, hormone-naïve 
patients to treatment with GM-CSF in the current 
study suggest that thalidomide may augment the 
effects of GM-CSF in PSA-only, hormone-naïve 
patients. This hypothesis is currently being 
investigated.
Conclusion
This report provides further evidence of the efﬁ  -
cacy of GM-CSF in preventing rising PSA levels 
in hormone naïve patients with PSA-only advanced 
prostate cancer. These results indicate that further 
study of GM-CSF administration to hormone-
refractory patients is not warranted, but further 
study of a chronic dosing regimen for GM-CSF 
administration to hormone-naïve patients is 
recommended.
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Table 4. Toxicities.
Grade 1 Grade 2 Grade 3 Grade 4
Non-Hematologic 
Toxicities
Edema 1 0 0
Fever 1 0 0
Chills 1 0 0
Bruising 1 0 0
Pain 1 0 0
Thrombosis 0 0 1
Hematologic toxicities
Leukopenia 2 5 1 0
Neutropenia 0 3 1 1
Lymphopenia 0 1 0 0
Hyperglycemia 6 1 0 0
Neutrophilia 3 2 0 0
Anemia 2 0 0 0
Elevated Leukocytes 1 5 0 0
Eosinophilia 1 1 0 0